Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral SHR0302 (Ivarmacitinib) in Moderate to Severe Atopic Dermatitis
NCT04875169Phase 3Completed
- Sponsor
- Reistone Biopharma
- Start
- Apr 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of ivarmacitinib in atopic dermatitis (AD), sponsored by Reistone Biopharma. Started Apr 2021; status: completed.
02
Drugs
ivarmacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04875169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04875169.